Increasing Cases of Shingles in the Eye Raise Key Questions
This Medical News article examines the increasing incidence of herpes zoster ophthalmicus —shingles of the eye—and the need for more widespread vaccination against shingles.
Authors: Yin D, Van Oorschot D, Jiang N, Marijam A, Saha D, Wu Z, Tang H, Diaz-Decaro J, Watson P, Xie X, Ren Y, He Y, Feng Y Abstract INTRODUCTION: Herpes zoster (HZ) or shingles occurs as a result of reactivation after a primary infection with varicella zoster virus (chickenpox). The burden of HZ in older adults in China is not well understood. We conducted a systematic literature review to understand the burden of disease related to HZ, its complications, and associated costs in China. AREAS COVERED: Using publications retrieved from Chinese and English literature databases, we described incidence and preval...
ConclusionsVaccination rates among Canadian patients with RA are suboptimal.
CONCLUSION: prompt diagnosis, through fundus examination and FA, and proper antiviral therapy were the mainstays to counteract the posterior uveitis. Nowadays, vaccination is a safe weapon to efficaciously reduce the ZVZ incidence among general population. PMID: 32644840 [PubMed - as supplied by publisher]
(Reuters Health)—The live herpes zoster vaccine does not provide reliable long-term protection in rheumatoid arthritis (RA) patients taking tofacitinib, a recent study suggests. Current ACR guidelines conditionally recommend that patients with RA who are 50 years and older be vaccinated against herpes zoster prior to starting therapy with the Janus kinase (JAK) inhibitor tofacitinib or... [Read More]
Herpes zoster, otherwise known as shingles, can be a devastating complication after heart transplantation due to persistent and severe herpetic neuralgia. Our heart transplant patients are recommended to have the shingles vaccine prior to heart transplantation, but this is not always achieved. We sought to assess whether the shingles vaccine did indeed prevent clinical shingles development after heart transplantation.
Adults re-exposed to the herpes zoster virus found to be around 30% less likely to develop shingles Related items fromOnMedica GPs are dealing with growing flu rates Experts predict 'invigorated' winter flu Illness poorly managed in those with learning disability Flu activity appears to be nearing its peak Doctors can help overcome ‘vaccine hesitancy’
These reports provide an evaluation of the shingles vaccination programme in England from 2018 to 2019.
The Advisory Committee on Immunization Practices (ACIP) recommends that adults aged ≥19 years receive various vaccines to prevent serious health conditions, including hepatitis B, herpes zoster/shingles, human papilloma virus (HPV), and pneumonia. Recent vaccine approvals by the US Food and Drug Administration (FDA) have led to updates in the ACIP adult immunization schedule. Thi s article provides a relevant clinical literature review for nurse practitioners on the newly approved vaccines for hepatitis B and herpes zoster and updated ACIP recommendations.
This NIHR Signal says that the risk of shingles is about 10% per year in adults after autologous stem cell transplant. The evidence summary indicates that two doses of deactivated herpes zoster vaccine could be a safe and effective way to reduce that risk by about two thirds.This effect is similar to another, heat-treated, non-live vaccine. Either vaccine could reduce the pain and need for medical treatment associated with shingles, and long-lasting complications such as post-herpetic neuralgia. It's not yet known if people need to continue taking acyclovir as well.